Kanion Pharmaceutical(600557) 证券日报·2025-04-29 23:38Core Viewpoint - The company has reported a significant decline in revenue and costs for its main products in the first quarter of 2025, primarily due to decreased sales of specific injection and oral liquid products [11]. Financial Data - The company completed the acquisition of 100% equity in Jiangsu Zhongxin Pharmaceutical Co., which is now a wholly-owned subsidiary and included in the financial statements [3]. - The company has not audited its first-quarter financial statements [10]. Non-Recurring Gains and Losses - The company has identified non-recurring gains and losses, but specific amounts and reasons are not detailed in the provided documents [4]. Shareholder Information - The company has implemented a share repurchase plan, extending the repurchase period by 9 months and increasing the maximum repurchase price from 18 RMB to 20 RMB per share [6]. - As of February 5, 2025, the company repurchased a total of 12,338,346 shares for approximately 185.91 million RMB [7]. - The controlling shareholder's action plan to increase holdings was completed, with 2,478,700 shares purchased for approximately 34.23 million RMB [8]. Product Development - The company has received clinical trial approval for several products, including solid granules and capsules for specific indications [8]. - The focus areas for Jiangsu Zhongxin Pharmaceutical include metabolic and neurological diseases, with multiple innovative drugs in various clinical trial phases [9].